Sirolimus
RDCRN 5702
Phase 3 small_molecule completed
Quick answer
Sirolimus for Lymphangioleiomyomatosis is a Phase 3 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Lymphangioleiomyomatosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed